AC-262, officially named AC-262356, is a research chemical belonging to the SARMs category. It was initially developed by Acadia Pharmaceuticals and, like other SARMs, shows a binding affinity to the androgen receptor. However, it is characterized by distinctive features that differentiate it from other SARMs and merit its scientific exploration.
AC-262’s chemical formula is C18H18F3N3O6. Its molecular structure features a trifluoromethyl group, contributing to its unique properties and potentials within the SARMs group. The compound has a molar mass of 441.36 g/mol and is generally presented in powder form. It is highly soluble in organic solvents such as DMSO and ethanol.
Mechanism of Action:
The mechanism of action of AC-262 centers on its selective binding affinity to androgen receptors. It has been shown to exhibit a particular selectivity for muscle and bone tissue, minimizing interactions with other androgenic tissues. This selective affinity marks AC-262 as a potential tool for applications requiring tissue-specific modulation of androgenic activity.
Potential Benefits and Applications: AC-262 is under investigation for several potential benefits, underpinning its scientific and medical interest.
Muscle and Bone Health:
AC-262’s selective affinity for muscle and bone tissue hints at its potential application in muscle wasting and osteoporosis management. Preclinical models suggest its efficacy in preserving lean muscle mass and enhancing bone mineral density. However, human studies are yet to establish this conclusively.
AC-262, with its partial agonistic action on androgen receptors, could play a role in hormonal balance. Its lower androgenic ratio compared to testosterone suggests that it could deliver anabolic benefits with a diminished risk of androgenic side effects. It thus warrants further investigation for conditions associated with androgenic imbalance, such as hypogonadism.
Preliminary studies have shown a potential positive impact of AC-262 on cognitive functions. Its action on androgen receptors could potentially influence neural health and cognitive performance, although this is a burgeoning field of research.
Limitations and Considerations:
While AC-262 shows promising attributes, it is essential to underscore that it remains an investigational compound, not yet approved for therapeutic use by regulatory bodies. Additionally, as an exogenous compound, AC-262 has the potential to influence endogenous hormonal systems, with unknown long-term effects.
AC-262 represents an intriguing avenue of research within the SARMs category, offering potential benefits for muscle and bone health, hormonal balance, and cognitive function. As the scientific community continues to unravel its properties, we hope for further elucidation of its potentials and limitations in the broader context of human health and disease management.
For laboratory and research purposes only. Must be handled by qualified and licensed professionals. Bodily introduction of any kind into humans and/or animals is strictly forbidden by law.